TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19
TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Buy and raises the price target from $17 to $19.
Read original at benzingaStocks · News reference
Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.408B Est
Surgery Partners (NASDAQ:SGRY) affirms FY2026 sales outlook from $3.350 billion-$3.450 billion to $3.350 billion-$3.450 billion vs $3.408 billion estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 1:04 PM
- Checked
- Jul 24, 2026, 1:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19
RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $20 to $19.
Read original at benzingaCantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $18 price target.
Read original at benzinga8-K filing — Surgery Partners, Inc. (SGRY)
Filed: 2026-08-10 AccNo: 0001638833-26-000074 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar